期刊文献+

静脉注射双膦酸盐治疗更年期骨质疏松症疗效分析 被引量:7

The efficacy analysis of intravenous bisphosphonate for the treatment of postmenopausal osteoporosis
下载PDF
导出
摘要 目的探讨双膦酸盐(艾本)治疗老年骨质疏松症的临床疗效。方法选择60例更年期骨质疏松症患者随机分为对照组及实验组,实验组应用二膦酸盐2mg每三个月一次静滴,同时口服活性维生素D和钙剂,对照组给予平衡盐溶液每三个月一次,同时口服活性维生素D和钙剂。分别于治疗前和治疗后3个月、6个月、9个月、12个月进行骨密度测量。结果治疗后3个月和6个月骨密度增加不明显,治疗9个月和12个月后骨密度显著升高,与对照组有显著性差异(P<0.01)。结论使用二膦酸盐治疗骨质疏松,能在一定程度上抑制骨丢失,增加骨密度,治疗骨质疏松,改善老年骨质疏松患者的生活质量。 Objective To explore the clinical efficacy of the bisphosphonate (Albert) for the treatment of osteoporosis in the elderly. Methods Sixty postmenopausal osteoporosis patients were selected and divided into the control group and the experimental group. The patients in the experimental group were treated with 2mg intravenous bisphosphonate, once every 3 months, and oral vitamin D and calcium. The patients in the control group were treated with the balanced salt solution, once every 3 months, and oral vitamin D and calcium. Bone mineral densities were measured before the treatment, and 3, 6, 9, and 12 months after the treatment. Results The bone mineral densities of the patients in experimental group did not increased obviously on 3 and 6 months after the treatment. However, they increased significantly 9 and 12 months after the treatment. The difference was significant comparing with those in the control group (P 〈 0. 01 ). Conclusion The bisphosphonate use for the treatment of can inhibit bone loss in some degree, and increase bone mineral density, and improve the life quality of the elder osteoporosis patients.
出处 《中国骨质疏松杂志》 CAS CSCD 2011年第7期587-588,604,共3页 Chinese Journal of Osteoporosis
关键词 双膦酸盐 骨质疏松 骨密度 Bisphosphonate Osteoporosis Bone mineral density
  • 相关文献

参考文献8

  • 1Nguyen ND,Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res,2006,21 (2) :340-349. 被引量:1
  • 2刘忠厚主编..骨质疏松学[M].北京:科学出版社,1998:790.
  • 3Felsenberg D, Miller P, Armbrecht G, et al. Oral iban - onate significantly reduces the risk of vertebral fractures of greater severity after 1,2, and 3 years in postmenopausal women with osteoporosis. Bone,2005,37 ( 5 ) :651-654. 被引量:1
  • 4Bauer DC, Gamero P, Hochberg MC, et al. Pretreatment levels ofbone turnover and the antifraeture efficacy of alendronate: the fracture intervention trial, Bone Miner Res,2006,21 (2) :292-299. 被引量:1
  • 5Adachi JD, Rizzoli R, Boonen S, et al. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis : a recta-analysis of individual patient data. Aging Clin Exp Res,2005,17(2) :150-156. 被引量:1
  • 6Frieder B, Graham R, Russell G. lbandronate in osteoporosis: preclinieal data and rationale for intermittent dosing. Osteoporos 1nt,2004,15:423-433. 被引量:1
  • 7Reid DM. Once-monthly dosing: an effective step forward. Bone, 2006,38 (4 Suppl 1 ) : 18-22. 被引量:1
  • 8Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med, 2007. [ e-publication 10. 1056/NEJMoa074941 at www. nejm. org]. 被引量:1

同被引文献53

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部